+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treosulfan vs leuprorelin in platin- and paclitaxel-resistant ovarian cancer Final analysis of the German AGO-Study Group trial OVAR 21



Treosulfan vs leuprorelin in platin- and paclitaxel-resistant ovarian cancer Final analysis of the German AGO-Study Group trial OVAR 21



European Journal of Cancer 37(Supplement 6): S325




(PDF emailed within 0-6 h: $19.90)

Accession: 035985738

Download citation: RISBibTeXText

DOI: 10.1016/S0959-8049(01)81694-4


Related references

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology 114(2): 199-205, 2009

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic Oncology 105(1): 132-137, 2006

Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel A prospective randomised phase III study of the AGO Ovarian Cancer Study Group. EJC Supplements 1(5): S16, 2003

Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. Seminars in Oncology 24(5 Suppl 15): S15-44-S15-52, 1997

Treatment of patients with advanced ovarian cancer with cisplatin/paclitaxel or carboplatin/paclitaxel - An interim analysis of the ago study protocol ovar-3. European Journal of Cancer 35(SUPPL 4): S231, Sept, 1999

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Annals of Oncology 13(2): 251-257, 2002

Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International Journal of Gynecological Cancer 19(1): 109-115, 2009

Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR). Journal of Clinical Oncology 23(16_suppl): 5004-5004, 2016

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecologic Oncology 96(2): 444-451, 2005

Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group. Urologia Internationalis 56 Suppl 1: 23-30, 1996

3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group. Journal of International Medical Research 18 Suppl 1: 103-113, 1990

Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer Intergroup phase III trial of the AGO OVAR and GINECO. Journal of Clinical Oncology 23(16_suppl): Lba5007-Lba5007, 2016

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute 98(15): 1036-1045, 2006

Study by the Working Group in Gynecologic Oncology for therapeutic optimization in advanced FIGO IIb-IV ovarian carcinoma: cisplatin-paclitaxel vs. carboplatin-paclitaxel. AGO Protocol Ovar-3. Zentralblatt für Gynakologie 118(6): 379-374, 1996

Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC. International Journal of Gynecological Cancer 15(Supplement S3): 224-225, 2005